efficacy

Gebauer K, Spelman L, Yamauchi PS, Bagel J, Nishandar T, Crane M, Kopeloff I, Kothekar M, Yao SL, Sofen HL. Efficacy and safety of tildrakizumab[...]

By sjmartinez • June 22, 2024

Fishbane S, Clegg DJ, Lerma EV, Rastogi A, Budden J, Morin I, Wen W, Menzaghi F, Topf J. Difelikefalin in Black/African American Hemodialysis Patients with[...]

By sjmartinez • June 4, 2024

Hoeper MM, Ewert R, Jansa P, Sirenko Y, Skride A, Balagtas C, Hackley S, Vogt S, Abreu P, Haughie S, Hassan T, Oudiz RJ. Randomized,[...]

By sjmartinez • May 16, 2024

Masson R, Park SE, Shih T, Hogeling M, Shi VY, Hsiao JL. Spironolactone in hidradenitis suppurativa: a single-center. Int J Womens Dermatol. 2024 Mar 19;10(1):e135.[...]

By sjmartinez • March 20, 2024

Corren J, Szefler SJ, Sher E, Korenblat P, Soong W, Hanania NA, Berman G, Brusselle G, Zitnik R, Natalie CR, Sun L, Siu K, Wu[...]

By sjmartinez • February 16, 2024

Kingston P, Blauvelt A, Strober B, Armstrong AW. Deucravacitinib: a novel TYK2 inhibitor for the treatment of moderate-to-severe psoriasis. J Psoriasis Psoriatic Arthritis. 2023 Oct;8(4):156-165.[...]

By sjmartinez • January 8, 2024

Rader F, Oręziak A, Choudhury L, Saberi S, Fermin D, Wheeler MT, Abraham TP, Garcia-Pavia P, Zwas DR, Masri A, Owens A, Hegde SM, Seidler[...]

By sjmartinez • January 8, 2024

Chen DH, Lenz HJ, Lechner MG, Angell TE. Reduced Tumor Size of Untreated Papillary Thyroid Carcinoma After Immune Checkpoint Inhibitor-Induced Thyroiditis. AACE Clin Case Rep.[...]

By sjmartinez • September 22, 2023

Masson R, Seivright J, Shih T, Bennett RG, Hogeling M, Shi VY, Hsiao JL. Trimethoprim/sulfamethoxazole and cephalexin combination therapy in hidradenitis suppurativa patients: A series[...]

By sjmartinez • June 19, 2023

Rastogi A, Fishbane S, Lerma E. Difelikefalin for the treatment of moderate-to-severe pruritus associated with chronic kidney disease on hemodialysis. Expert Rev Clin Pharmacol. 2023[...]

By sjmartinez • April 4, 2023